Who
John Maraganore
Director
Company insider
Files Form 4 as: Director, City Therapeutics; Director, Takeda Pharmaceutical Company; Director, Kymera Therapeutics; Director, Rapport Therapeutics; Director, Beam Therapeutics; Director, Hemab Therapeutics Holdings; Director, ProKidney; Director, Agios Pharmaceuticals.
In numbers
- Trades disclosed
- 617
- Buys
- 12
- Sells
- 53
- Bought
- $1.9M
- Sold
- $137.8M
- Companies
- 11
- Companies where not an officer
- 10
- First trade
- 12 May 2006
- Last trade
- 19 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 2 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 19 Oct 2026 | CTY City TherapeuticsBiotechnology | SEC FORM 4 Code C | —610,759 | filing |
| 19 Oct 2026filed 19 Oct 2026 | CTY City Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —500,000 at $0.00 | filing |
| 19 Oct 2026filed 19 Oct 2026 | CTY City Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —56,095 at $0.00 | filing |
| 15 Oct 2026filed 19 Oct 2026 | CTY City Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,649 at $0.00 | filing |
| —filed 6 Jul 2026 | TAK Takeda Pharmaceutical Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | $5.7M1,152 at $4,931.20 | filing |
| —filed 6 Jul 2026 | TAK Takeda Pharmaceutical Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | $5.7M1,152 at $4,931.20 | filing |
| 1 Jul 2026filed 6 Jul 2026 | TAK Takeda Pharmaceutical CompanyPharmaceuticals | SEC FORM 4 Code A | —3,800 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | TAK Takeda Pharmaceutical Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,319 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | TAK Takeda Pharmaceutical Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,319 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | TAK Takeda Pharmaceutical CompanyPharmaceuticals | SEC FORM 4 Code A | —3,800 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,068 at $0.00 | filing |
| 24 Jun 2026filed 25 Jun 2026 | KYMR Kymera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,068 at $0.00 | filing |
| 10 Jun 2026filed 10 Jun 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 10 Jun 2026filed 10 Jun 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,676 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,676 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | COAG Hemab Therapeutics HoldingsBiotechnology | SEC FORM 4 Code C | —17,974 | filing |
| 4 May 2026filed 4 May 2026 | COAG Hemab Therapeutics HoldingsBiotechnology | SEC FORM 4 Code C | —17,974 | filing |
| 4 May 2026filed 4 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —817 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | COAG Hemab Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code C | —817 at $0.00 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) versus Oncocyte (NASDAQ:IMDX) Head to Head ComparisonALNY · dailypolitical.com · 21 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical SurveyALNY · themarketsdaily.com · 20 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026Agios Pharmaceuticals (NASDAQ:AGIO) Stock Gets Price Target Reduction from Truist FinancialAGIO · themarketsdaily.com · 10 Oct 2026
0 headlines in the last 90 days name John Maraganore; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.